Rhythm Pharmaceuticals (RYTM) PT Lowered to $16 at Goldman Sachs, Following Earnings
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Price: $38.11 --0%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 7
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 7
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $16.00 (from $23.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EasyJet Plc. (EZJ:LN) (ESYJY) PT Raised to GBP750 at BofA Securities
- BayCom Corp (BCML) Misses Q1 EPS by 4c
- Goldman Sachs First Take on Netflix (NFLX): 'We expect the market to have a muted reaction'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
